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Abstract
Background: Stress echocardiography (SE) has an established role in evidence-based guidelines, but recently its
breadth and variety of applications have extended well beyond coronary artery disease (CAD). We lack a
prospective research study of SE applications, in and beyond CAD, also considering a variety of signs in addition to
regional wall motion abnormalities.
Methods: In a prospective, multicenter, international, observational study design, > 100 certified high-volume SE
labs (initially from Italy, Brazil, Hungary, and Serbia) will be networked with an organized system of clinical,
laboratory and imaging data collection at the time of physical or pharmacological SE, with structured follow-up
information. The study is endorsed by the Italian Society of Cardiovascular Echography and organized in 10
subprojects focusing on: contractile reserve for prediction of cardiac resynchronization or medical therapy response;
stress B-lines in heart failure; hypertrophic cardiomyopathy; heart failure with preserved ejection fraction; mitral
regurgitation after either transcatheter or surgical aortic valve replacement; outdoor SE in extreme physiology; right
ventricular contractile reserve in repaired Tetralogy of Fallot; suspected or initial pulmonary arterial hypertension;
coronary flow velocity, left ventricular elastance reserve and B-lines in known or suspected CAD; identification of
subclinical familial disease in genotype-positive, phenotype- negative healthy relatives of inherited disease (such as
hypertrophic cardiomyopathy).
Results: We expect to recruit about 10,000 patients over a 5-year period (2016-2020), with sample sizes ranging
from 5,000 for coronary flow velocity/ left ventricular elastance/ B-lines in CAD to around 250 for hypertrophic
cardiomyopathy or repaired Tetralogy of Fallot. This data-base will allow to investigate technical questions such as
feasibility and reproducibility of various SE parameters and to assess their prognostic value in different clinical
scenarios.
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Conclusions: The study will create the cultural, informatic and scientific infrastructure connecting high-volume,
accredited SE labs, sharing common criteria of indication, execution, reporting and image storage of SE to obtain
original safety, feasibility, and outcome data in evidence-poor diagnostic fields, also outside the established core
application of SE in CAD based on regional wall motion abnormalities. The study will standardize procedures,
validate emerging signs, and integrate the new information with established knowledge, helping to build a
next-generation SE lab without inner walls.
Keywords: Effectiveness, Imaging, Prognosis, Stress echocardiography
Background
For a long time, the scope of stress echo (SE) remained
focused on coronary artery disease (CAD) [1, 2]. In the
last ten years, SE has exploded in its breadth and variety
of applications [3, 4]. From a one-fits-all approach (wall
motion by 2D-echo in the patient with known or sus-
pected CAD), the field has progressed to an omnivorous,
next-generation laboratory employing a variety of tech-
nologies (from M-Mode to 2D, from pulsed, continuous,
color and tissue Doppler to lung ultrasound) on patients
covering the entire spectrum of severity (from elite ath-
letes to patients with end-stage heart failure) and ages
(from children with congenital heart disease to the elderly
with aortic stenosis) [4] (Fig. 1). As a consequence of this
rapid growth, the clinical use of SE often lacks the neces-
sary supportive evidence and is slowed by unavoidable
confusion on methodological issues in a rapidly evolving
field. This situation represents a challenge and an oppor-
tunity for the SE community. It is a challenge, because in
other fields of cardiology we currently lack the level of evi-
dence collected in the last 30 years that led SE based on
the detection of regional wall motion abnormalities to play
a central role in CAD and heart failure management, as
acknowledged in specialty [5, 6] and general cardiology
guidelines [7–10]. It is also an opportunity, because today
SE has the unprecedented advantages of economic sus-
tainability, lack of radiation, portability and versatility
making it especially attractive in the current era of in-
creasing societal concerns about cardiac imaging costs
and long-term risks due to ionizing radiation [11].
“Stress echo 2020” (SE2020) is a prospective, multicen-
ter, international, observational study, involving > 100 SE
laboratories, with short-term, mid-term, and long-term
aims: 1) In the short term (12 months), to create the cul-
tural, digital and scientific infrastructure connecting high
volume, accredited SE labs, sharing common criteria of
indication, performance, reporting and image storage of
SE; 2) In the mid-term (2 to 3 years), to obtain original
safety, feasibility, and outcome data in evidence-poor
diagnostic fields, also outside the established core appli-
cation of SE in CAD [12]: contractile reserve for predic-
tion of cardiac resynchronization or medical therapy
response; stress B-lines in heart failure; hypertrophic
cardiomyopathy; heart failure with preserved ejection
fraction; mitral and aortic valve function after transcath-
eter or surgical aortic valve implantation; outdoor SE in
extreme physiology; right ventricular contractile reserve
in repaired Tetralogy of Fallot; exercise-induced pul-
monary artery pressure rise in predicting outcome in at
risk, borderline or early established pulmonary arterial
hypertension; added value of new, second- and third-
generation parameters (coronary flow velocity reserve,
left ventricular elastance reserve and B-lines) for refining
prognosis based on regional wall motion abnormalities,
within and outside CAD; identification of subclinical
familial disease in genotype-positive and phenotype–
negative healthy relatives at risk for hypertrophic car-
diomyopathy or familial dilated cardiomyopathy or
pulmonary hypertension; 3) In the long-term (at the
end of the 5-year project), to establish an up and
running platform for future prospective, randomized,
outcome studies with selective interventions on spe-
cific diseases based on SE results.
Methods
In a prospective, multicenter, international, observational
study design, > 100 SE labs will be networked with sys-
tematic clinical, laboratory and imaging data collection at
the time of SE and with structured follow-up information.
The study theater is the international network of cardi-
ology SE laboratories, and the study is endorsed and pro-
moted by the Italian Society of Cardiovascular Echography.
The main documents (from protocols to case report form
to software and website platform) will be in English, so that
selected highly motivated and experienced centers may join
specific subprojects, setting the stage for an international
upscaling of the project in the coming years. The starting
point of the recruitment phase was a recent electronic sur-
vey by the Italian Society of Cardiovascular Echography, in
2015 censoring 134 laboratories with moderate- (>100/
year) to high- (>400/year) volume SE activities [13], which
were precisely interrogated for interest in participation to
SE2020. Laboratories from Brazil, Serbia, and Hungary
have already joined the project. The recruitment plan fore-
casts 500 patients by the end of 2016, with doubling of the
rate of enrollment in subsequent years, in parallel with the
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increasing number of recruiting labs fulfilling quality con-
trol criteria, reaching the target number of 100 at the end
of the 5-year schedule.
Data collection
As recommended by guidelines, we will adopt a 17-
segment model of the left ventricle, with 1-to-4 segmental
scoring system [5, 6]. Stress protocols are harmonized ac-
cording to recent European and North-American scien-
tific societies' guidelines, with semi-supine exercise
recommended and pharmacological stress dosages up to
40 mcg/kg/min for dobutamine, up to 0.84 mg/kg in
6 min for dipyridamole, and up to a 4-min step of 200
microg/kg/min for adenosine [5, 6]. With dobutamine, at-
ropine (up to 1 mg) can be administered in patients with
suspected CAD (protocol 9), and it is associated with a
higher rate of complications in those with a history of
neuropsychiatric symptoms, reduced left ventricular func-
tion, or small body habitus. The maximal allowed dobuta-
mine dose is 20 mcg/kg/min in patients with aortic
stenosis, in whom higher doses are less safe and prob-
ably unnecessary [13]. All laboratories will share a
standardized case report form coded in a database
format to facilitate retrieval and communication. For
applications outside CAD and for CAD testing with
vasodilator stress, no atropine is given on top of
pharmacological stress.
Although data collection with a dedicated project-
specific case report form is allowed, we encourage imple-
menting a dedicated, free ad-hoc system for data storage
and reporting developed at the National Research Council,
Institute of Clinical Physiology. The software provides a
suitable informatics infrastructure for the SE 2020 Italian
multicenter study, with an intuitive graphic interface, eye-
catching graphic format and convenient reporting option.
It could represent the trade-off between the comprehen-
sive information required by scientific standards and the
smooth workflow priority of busy, high-volume, clinically-
driven activities [14]. As an illustrative example, the report
page for regional wall motion abnormalities and Wall
Motion Score Index is shown in Fig. 2. The software
was developed and tested in Italian and the transla-
tion of the last release in other languages (English,
Portuguese and Serbian) is currently in progress.
Data analysis
Data will be expressed as mean ± standard deviation
(normally distributed data, such as wall motion score















Valvular HD Congenital HD Extreme physiology Pulmonary arterial
hypertension
HCM
Fig. 1 In the box, the contemporary spectrum of patients for whom SE can offer potentially unique diagnostic information: coronary artery
disease; heart failure (with either reduced or preserved left ventricular function); hypertrophic cardiomyopathy; valvular heart disease; extreme
physiology; adult repaired congenital heart disease; early, at risk, or borderline pulmonary arterial hypertension. For each clinical condition, a
different key SE parameter can be used, evaluated at rest (left column) and during stress (right column), maximizing the versatility of the
technique. From top to bottom rows, regional wall motion (for ischemia and viability), coronary flow velocity reserve (CFVR), mitral insufficiency,
end-systolic volume of the left ventricle (necessary to assess left ventricular elastance), and B-lines (a marker of extravascular lung water). Modified
and adapted from ref 4 (Picano and Pellikka [4])
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index), median and inter-quartile (25th, 75th) range
(non-normally distributed data, such as B-lines) or per
cent frequency (categorical data, such as presence or
absence of severe mitral regurgitation), with absolute
numbers. In patients with coronary angiographic informa-
tion, diagnostic sensitivity, specificity, positive and nega-
tive predictive value will be assessed for any combination
of the wall motion score index, coronary flow velocity
reserve, left ventricular contractile reserve and B-lines.
One-sample comparisons will be performed using
Wilcoxon test, and the chi-squared test without Fish-
er's correction for categorical data. Event rates will be
estimated with Kaplan–Meier curves and compared
by the log-rank test. Univariable analyses by Cox pro-
portional hazards models will be performed to assess
the association between each candidate variable and
outcome. All variables with P <0.20 by univariable
analysis will be considered as candidate variables for
the multivariable analyses. Goodness of fit of the
models will be based on C-statistics and its variants,
adjusting for optimism using bootstrap replications
(at least 1000). A receiver operating characteristic
analysis will be used to obtain the best prognostic
predictor for the individual SE variables. We will also
analyze the data according to a clinically guided step-
wise procedure, where the variables will be included
in the model in the same order in which they are ac-
tually considered by the cardiologist. Statistical signifi-
cance will be set at p < 0.05.
Quality control
It is well-known that the diagnostic performance of SE is
closely related to the level of expertise of the
cardiologist-echocardiographer performing the test,
since the evaluation of regional wall motion is subjective
and qualitative, with considerable variability even among
experienced centers of undisputed reputation [15]. The
reproducibility and accuracy of wall motion reading can
be substantially increased with limited training [16] and
through development of conservative, pre-specified
reading criteria [17]. Therefore, quality control of the
diagnostic performance in the various laboratories is a
must in order to enter meaningful information in the
data bank. The burden of quality control is on the hub
center of the principal investigator of each subproject,
where various spoke centers may converge. For the
Fig. 2 The computerized case report form for the regional wall motion abnormalities of the SE 2020 study. The grading of the response is
reported in tabular (right side, lower panel) and graphic (right side, upper panel) format, with normal values of Wall Motion Score Index in green,
mild impairment in yellow, moderate in orange, and severe impairment in red
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general project, the hub center for regional wall motion
analysis is Pisa-CNR, in coordination with the principal
investigator. There are five different levels of quality
control, with increasing levels of complexity:
1. Level 1, pre-requisite: a volume activity of the lab of at
least 100 SE tests per year, which is the requirement for
credentialing of SE activity by scientific societies [18].
2. Level 2, spoke centers read hub SE images,
consisting in 20 selected studies for regional wall
motion analysis. The concordance requires
identification of test negativity/positivity and, in
positive tests, the correct localization of the ischemic
zone. For each test, a multiple choice 6-answer test is
given. The criterion of ≥ 90% concordance (at least 18
out of 20 studies) is required, as previously described
for first-generation SE multicenter studies [19, 20].
3. Level 3, hub centers read spoke centers studies,
consisting in 20 any-quality consecutive studies
recorded by the spoke center. The criterion of ≥ 80%
concordance (at least 16 out of 20 studies) is
required, as previously described for first-generation
SE multicenter studies [19].
4. Level 4, core lab reading. All centers should grant
full access to images of SE studies entered in the
data bank for audit or reading by core lab laboratory,
which is the standard for specific subprojects such
as number 10 for genetic SE, when every effort
needs to be made to minimize variability and a
single reader will analyze all studies acquired by
different centers, as required by recommendations
for small-to-medium sample studies, when resources
allow [20].
5. Level 5, specific protocols quality control. Although
the SE quality control has proved to work well for
regional wall motion analysis, novel SE applications
involve different parameters, methodology of
acquisition and reading criteria. Therefore, for each
subproject, a web-based training session and quality
control is organized by the specific hub center and
principal investigator to assure consistency of data
[21]. The principal investigator of each subproject
will prepare a set of 20 studies with rest-stress
images. For each test, a multiple choice 6-answers
test is given (only 1 correct). The criterion of ≥90%
concordance (at least 18 out of 20 studies) is
required. The specific signs tested for certification
are: end-diastolic and end-systolic volume changes
(protocol 1); B-lines (protocol 2, 4, 6 and 9); left
ventricular outflow tract gradient (protocol 3 and 10);
E/e' (protocol 4); mitral regurgitation quantitative
assessment (protocol 5); aortic stenosis quantitative
assessment (protocol 5); right ventricular function
(protocol 7); pulmonary arterial systolic pressure
measurements during stress (protocol 8); coronary
flow velocity reserve (protocol 9); left ventricular elas-
tance (protocol 9); global longitudinal strain (protocol
4 and 10).
This study is also intended as a special level of voluntary
accreditation and expertise in the specific field of interest,
well above the volume activity criteria requested by guide-
lines. The accreditation process is run and certified by the
Italian scientific society of echocardiography strictly follow-
ing criteria and procedures of the European association of
cardiovascular imaging to ensure standardization and inde-
pendence of the process. When not otherwise specified,
resting and SE measurements are performed according to
the latest joint recommendations of European and North-
American societies [22]. A simplified view of each lab's road
to SE2020 is shown in Fig. 3: the essential pre-requisite is
the high-volume activity of the lab, with readers' certifica-
tion of competence from national or international societies
and written declaration of interest in SE2020. After adop-
tion of dedicated SE computerized software by the lab
(allowing direct entry of the information in a format com-
patible with the data bank) and voluntary certification for
project-specific SE reading, the center can start recruiting.
Overall study design
We will collect the experience of Italian, Brazilian,
Hungarian and Serbian SE labs over the 5-year period
from 2016 to 2020. In this broader framework, 10
sub-projects will address specific patients’ subsets.
The target population ranges from 250-patient sam-
ples for protocols focused on specific diseases (such
as protocol 7 in repaired tetralogy of Fallot) to 2,500
for protocols on heart failure (number 2) to 5,000 to
all-comers with known or suspected CAD tested with
novel indices (number 9) (Table 1).
Different study projects will cover the entire spectrum
of disease, age and clinical status of current patients.
The recruited participants are “the wellest of the well”
(super-fit athletes entering project 6), the “worried well”
(young first-degree relatives of patients with hyper-
trophic cardiomyopathy or familiar forms of dilated car-
diomyopathy or pulmonary arterial hypertension, in
project 10), the “suspected sick” (for instance patients
with suspected diastolic heart failure or CAD as in pro-
jects 4 and 9), up to the "sickest of the sick" (for in-
stance, patients with advanced heart failure or valvular
heart disease entering projects 1, 2 and 5). Some degree
of overlap is unavoidably present for some projects, for
instance with subjects eligible for project 2 who are also
recruitable for project 1 (if they undergo cardiac resyn-
chronization therapy) or for project 5 (if they have heart
failure with preserved ejection fraction). Over time,
patients may move from one project to another: for
Picano et al. Cardiovascular Ultrasound  (2017) 15:3 Page 5 of 21
Fig. 3 The road to SE2020 for the individual stress echo laboratories. The overall recruitment plan for SE2020 targets 10,000 patients by the end
of 2020
Table 1 The 10 subprojects
Number Acronym Patients Main parameter Sample
size
1-Cardiac Resynchronization Therapy forecast CHEF Prior to cardiac resynchronization therapy Wall Motion Score Index 500
2-B-lines in heart failure BHEF Heart failure Left ventricular Contractile
Rererve
2,500
3-SE in Hypertrophic cardiomyopathy SEHCA Hypertrophic cardiomyopathy Left ventricular outflow tract
gradient
250
4- SE in diastolic heart failure SEDIA Heart failure preserved ejection fraction E/e’ 250
5-SE in Transvalvular or surgical aortic valve
replacement
SETA After aortic valve replacement Mitral insufficiency 250
6-SE outdoor SEO Extreme exercise B-lines 250
7-SE in repaired tetralogy of Fallot SETOF Repaired Fallot Tricuspid annular plane systolic
excursion
250
8-Doppler SE in pulmonary arterial
hypertension





9-Diagnosis of CAD by triple imaging SE DITSE Known or suspected CAD Coronary Flow velocity reserve 5,000
10-Genetic SE GENES Preclinical dilated or hypertrophic
cardiomyopathy
Left ventricular outflow tract
gradient
250
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instance, first-degree relatives of hypertrophic cardiomy-
opathy patients with negative phenotype enrolled in pro-
ject 10 may subsequently develop overt forms of disease
and be enrolled in project 3. All these potential gray-
zone situations will be readily identified in individual SE
reports. The investigator is allowed to enter the patient
in only one subproject at a given time.
Although the setting will be mainly the Italian cardio-
logical community, all essential documents will be written
in English and we plan to extend the project to other com-
munities with long-standing history of cooperation and
experience in multicenter trials. Brazilian, Hungarian and
Serbian centers are already recruiting and additional labora-
tories from other countries are now entering the process of
accreditation. The project is curiosity-driven, independent
from sponsors, and clinically oriented. However, after the
planning and start-up phase, support from public or private
funding agencies or industries is possible – provided that it
is unrestricted and does not interfere in any way with data
collection and analysis.
There is no bonus payment for subject recruitment
and subject referral. Enrolled patients are referred to the
SE lab for clinically-driven indications. Each patient
signs an informed consent form allowing scientific
utilization of data, respectful of privacy rights, at the
time of testing. The study project was submitted by the
coordinating center of the principal investigator on
January 31, 2016 and approved in its revised form by the
Rome-1 ethical committee on July 20, 2016 (protocol
number 1487/Lazio1). Ethics committee approval will be
sought by each participating center, as needed.
Inclusion criteria shared by all projects are: 1- age <
85 years and > 18 years (except for project 7 regarding
repaired Tetralogy of Fallot and project 10 regarding healthy
relatives of patients with familial disease, in which chil-
dren > 10 years can enter the study after parental consent);
2- technically acceptable acoustic window at rest (with at
least 14 segments well visualized in at least one projection).
Exclusion criteria shared by all projects are: 1- pres-
ence of prognosis-limiting comorbidities, such as ad-
vanced cancer, reducing life expectancy to < 1 year; 2-
pregnancy/lactation; 3- unwillingness to give informed
consent and to enter a regular follow-up program.
SE data will be available to the referring physician.
A brief synopsis of each project is presented for each
sub-study, which places emphasis on different parame-
ters tailored on the specific diagnostic question (Fig. 4).
CHEF
Cardiac resynchronization tHErapy Forecast.
Background
Cardiac resynchronization therapy is increasingly used
in patients with heart failure, but the identification of
Fig. 4 The key echocardiographic parameter for each project, around the logo of SE2020. Clockwise: regional wall motion (project 1, but
important in all other projects, mainly project 9); end-systolic volume as part of left ventricular elastance assessment (project 2); left ventricular
outflow tract gradient (project 3, but also important in project 10); E/e' ratio (project 4); mitral insufficiency (project 5, but also important in project
2); B-lines (essential in project 6, but also important in project 2, 4 and 9); right ventricular function (project 7); pulmonary hemodynamics (project
8 and 10); regional coronary flow velocity reserve (useful in project 9, but also important in projects 2, 3 and 10)
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“responders” remains challenging, since up to 1 in 3 pa-
tients do not show symptomatic improvement with this
costly and demanding electrical therapy [10]. QRS width
remains the single established criterion to assess intra-
ventricular dyssynchrony according to guidelines; how-
ever, there is no accepted consensus on which imaging
parameter is best to predict cardiac resynchronization
therapy response. Inconsistent results have been ob-
tained with several echocardiographic indices of left ven-
tricular dyssynchrony [23]. The presence of myocardial
contractile reserve assessed during SE predicted the re-
sponse to cardiac resynchronization therapy: the use of
SE had obvious potential for a better selection of cardiac
resynchronization therapy candidates, in whom a pre-
served contractility is related to a higher percentage of
clinical and echocardiographic responders to cardiac
resynchronization therapy [24–27].
Aims
The primary aim is to evaluate the feasibility of several
indices of SE (including the well- established, such as
wall motion score index, and more innovative ones such
as left ventricular elastance) in the evaluation of patient
candidates for cardiac resynchronization therapy. The
secondary aim is to assess the value of each of these pa-
rameters (alone or in combination) in predicting the
symptomatic and functional improvement in the short-
term (1 week to 1 month) after electrical or medical
therapy. The tertiary aim is to assess the prognostic
value of SE indices for prognostic stratification in the
medium-long term.
Methods
Patients evaluated prior to cardiac resynchronization
therapy, with class I, IIa or IIb for cardiac resynchroniza-
tion therapy according to ESC 2016 guidelines [10], and
therefore with ejection fraction ≤ 35% (by 2-D Simpson
method, or real time 3D echocardiography) and QRS
duration ≥ 130 ms. Contractile reserve will be assessed
during stress (exercise or dobutamine or vasodilators)
through variations in Wall Motion Score Index and with
more advanced parameters such as left ventricular
elastance reserve, as the peak stress/baseline ratio of
end-systolic pressure/ end-systolic volume [28]. All
other echocardiographic parameters of interest (left
ventricular ejection fraction, E/e’, mitral regurgitation,
tricuspid annular plane systolic excursion, septal flash,
apical rocking, left anterior descending artery coronary
flow velocity whenever possible) will also be assessed at
baseline and peak stress. All patients will be followed-up
within 6-months to 1 year also with resting echocardio-
graphic examination to assess left ventricular remodelling
and recovery of function. Any patient excluded from car-
diac resynchronization therapy and kept on optimal
medical therapy will be included in the follow-up, since
the presence of contractile reserve may predict the func-
tional improvement in these patients as well [13].
Sample size calculation
If we assume a 60% response rate to cardiac resynchro-
nization therapy, with doubling of likelihood of improve-
ment in presence of a pre-test contractile reserve by SE,
with a power of 80% and an alpha error of 5%, a sample
size of 277 patients is required. About the same number
is required to predict the response to medical therapy in
patients eventually not undergoing cardiac resynchroni-
zation therapy.
Study hypothesis
The presence of contractile reserve is associated with a
better prognosis and greater chance of functional recov-
ery with cardiac resynchronization therapy.
BHEF
Evaluation of B-lines in HEart Failure patients with
depressed ejection fraction.
Background
B- lines are a semiquantitative sign of extravascular lung
water present in 1 out of 3 heart failure patients at rest
and in 1 out of 2 during stress, and potentially useful for
refining prognostic stratification and titrating diuretic
therapy in these patients. Their prognostic power is
higher during stress than at rest, and integrates the
powerful stratification provided by dynamic assessment
of other established predictors such as mitral regurgita-
tion, E/e’ as a surrogate of left ventricular filling pressure,
ejection fraction and tricuspid annular plane systolic ex-
cursion [29, 30].
Aims
The primary aim is to assess the feasibility of several in-
dices of SE (including the well- established such as left
ventricular ejection fraction and more innovative ones
such as B-lines or left anterior descending coronary flow
reserve) in evaluating patients with known or suspected
heart failure with reduced ejection fraction. The secondary
aim is to assess the value of each of these parameters in
predicting the functional impairment, indicated by New
York Heart Association class, cardiac natriuretic peptides
concentration, peak VO2 and other indices. The tertiary
aim is to assess the prognostic value of SE indices for
prognostic stratification in the medium-long -term.
Methods
We will enrol patients referred to SE (with exercise, do-
butamine or dipyridamole) with known or suspected
heart failure, with reduced (<40%) ejection fraction. B-
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lines will be scored with the 28-regions antero-lateral
chest assessment as previously described at baseline and
immediately after stopping exercise [31]. A simplified 8-
region or 4-region scan is also allowed in order to save
time without loss of critical information. All other echo-
cardiographic parameters of interest (left ventricular
ejection fraction, E/e’, mitral regurgitation, tricuspid an-
nular plane systolic excursion, left anterior descending
artery coronary flow velocity whenever possible) will also
be assessed at baseline and peak stress [32]. All patients
will be followed-up for at least 1 year.
Sample size calculation
If we conservatively assume a 30% yearly incidence of
composite end-points (death, myocardial infarction, new
hospital readmission, heart transplant, ventricular assist
device implantation, aborted sudden death) and a 5% in-
cidence of death, with doubling of likelihood of events in
presence of a positive SE (for B-lines increase during
stress or lack of contractile reserve or severe mitral in-
sufficiency), with a power of 95% and an alpha error of
5%, with an attrition rate of 15%, a sample size of about
2500 patients is required if the effect on mortality is
evaluated.
Study hypothesis
The integrated assessment of 5 major echocardiographic
variables during stress adds power to the prognostic
stratification operated by isolated echocardiographic pre-
dictors in heart failure patients. The prognostically mean-
ingful signs explore 5 key links in the patho-physiologic
chain behind cardiovascular response in heart failure: left
ventricular systolic function – left ventricular diastolic
function - mitral valve regurgitation - lung water accumu-
lation - right ventricular function.
SEHCA
Stress Echo in Hypertrophic Cardiomyopathy.
Background
The impact of SE in hypertrophic cardiomyopathy is
limited by lack of standardization and outcome data.
Current guidelines recommend SE solely for evaluation
of left ventricular outflow tract obstruction [33]. How-
ever, large-scale registry data show that SE positivity for
ischemic criteria (such as new wall motion abnormalities
and coronary flow velocity reserve) rather than inducible
gradients predict adverse outcome in hypertrophic car-
diomyopathy [34]. Thus, important prognostic as well as
functional information may be derived from SE, al-
though their clinical impact remains limited due lack of
standardized data collection and uniform protocols.
Currently there are virtually no two centers performing
SE in the same way in hypertrophic cardiomyopathy
patients, and the test remains grossly underutilized due
to (unjustified) concerns with safety. Prospective, stan-
dardized, multicenter data collection is necessary to
achieve comprehensive evaluation of SE potential in this
disease. Of note, exercise limitation and breathlessness
may be due to a number of different causes, including
left ventricular outflow tract obstruction (which may
increase, remain stable or decrease during exercise), func-
tional mitral regurgitation, restrictive physiology, ampli-
fied mechanical dyssynchrony, coronary microvascular
disease or – less frequently – ischemia associated with
prognostically unfavorable stress-induced wall motion ab-
normalities. Despite similar clinical manifestations, man-
agement may differ substantially based on the
mechanisms [35]. SE is the only test with the potential to
discriminate the various components, allowing a targeted
treatment driven by pathophysiology, but prospective data
are required to substantiate this hypothesis. Of note,
general consensus exists regarding the advisability of
preferring physiological provocation with exercise over
pharmacological stressors (particularly dobutamine due to
substantial prevalence of false positives with regard to in-
ducible obstruction).
Aims
The primary aim is to evaluate the feasibility of several
indices of SE (from the well- established such as left ven-
tricular outflow tract gradient to more innovative features
such as B-lines or left anterior descending coronary flow
reserve) in the evaluation of hypertrophic cardiomyopathy
patients. The secondary aim is to assess the value of each
of these parameters in predicting functional impairment,
indicated by New York Heart Association class, European
Society of Cardiology sudden cardiac death risk score and
other indices. The tertiary aim is to assess the prognostic
value of SE indices for prognostic stratification in the
medium-long-term.
Methods
Diagnosis of hypertrophic cardiomyopathy will be based on
existing guidelines [33]. Phenocopies such as infiltrative/
storage disease (eg, Fabry) will be excluded. Low-to-
intermediate risk symptomatic or asymptomatic hyper-
trophic cardiomyopathy patients will undergo exercise SE
with assessment at each stage and during recovery of wall
motion, mitral insufficiency, left ventricular outflow tract
gradient (in orthostatic position) and E/e’. If feasible, coron-
ary flow velocity reserve on left anterior descending and
lung ultrasound B-lines will also be assessed. Only when
patients are unable to exercise, or for the specific aim of
assessing coronary flow velocity reserve, will a vasodilator
stress (high dose dipyridamole or adenosine without
atropine) be performed. All patients will be followed-
up and the prognostic value of different rest and SE
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parameters (also compared to standard prognostic in-
dices) will be assessed.
Sample size calculation
The composite end-point of the study comprises death
(cardiovascular and all-cause), new hospital admission
for acute heart failure, newly onset atrial fibrillation,
aborted sudden death, heart transplant or ventricular as-
sist device implantation. A pilot study showed an inci-
dence of events around 8% per year [34]. If we assume a
positivity rate to SE (by composite criteria) of 40%, with
doubling of likelihood of events in presence of SE posi-
tivity (by any criteria), with a power of 80%, an alpha
error of 5%, and an attrition rate of 10%, a sample size
of about 250 patients is required.
Study hypothesis
Hypertrophic cardiomyopathy patients with inducible
wall motion abnormalities and reduced coronary flow
velocity reserve (or lung ultrasound B-lines) are at sub-
stantially higher risk for subsequent unfavorable events
than patients with normal wall motion and preserved
coronary flow velocity reserve. Exercise capacity predicts
outcome in hypertrophic cardiomyopathy patients inde-
pendent of the presence and magnitude of resting or
provocable obstruction.
SEDIA
Stress Echo in Diastolic Heart failure.
Background
Diastolic SE should be considered in the breathless pa-
tient with normal left ventricular ejection fraction, high
cardiac natriuretic peptides and low exercise tolerance,
especially in presence of cardiovascular risk factors
(advanced age, arterial systemic hypertension, diabetes
mellitus, obesity and sedentary lifestyle) after ruling
out other common cardiac (heart valve disease, coronary
artery disease) and non-cardiac causes of dyspnea (mainly
anemia and chronic obstructive pulmonary disease). « Red
flag » indicators of possible diastolic dysfunction include
left ventricular hypertrophy, enlarged left atrium and pul-
monary hypertension. During SE, findings which may
account for unexplained dyspnea beyond diastolic dys-
function are left ventricular outflow tract obstruction, dy-
namic mitral regurgitation, and new onset regional wall
motion abnormalities [36]. The diagnostic SE criteria of
heart failure with preserved ejection fraction are reduced
stroke volume and cardiac output reserve, high left ven-
tricular filling pressures (average E/e’ ratio > 14) and pul-
monary hypertension, which also identify patients with
more severe prognosis [37, 38]. In patients with heart fail-
ure and either preserved (>50%) or mid-range (40-49%)
ejection fraction, SE may allow the identification of
diastolic dysfunction in patients with parameters incon-
clusive at rest [10]. According to the latest 2016 recom-
mendations on the evaluation of left ventricular diastolic
function by echocardiography [36], diastolic stress testing
would not be indicated in patients with either completely
normal diastolic function at rest (in whom a severe dia-
stolic dysfunction is unlikely to develop during stress) and
in patients with ≥ grade 2 diastolic dysfunction at rest
(with elevated filling pressures at rest which will likely in-
crease further during exercise). However, testing of these
patients can be valuable to assess the incremental value, if
any, of newer candidate indices such as left ventricular
end-diastolic volume reserve and B-lines. In addition, also
patients with normal left ventricular diastolic function at
rest can indeed develop increase in left ventricular filling
pressures with dyspnea when exercising.
Aims
The primary aim is to evaluate the feasibility of several
indices of SE (including more established such as E/e' ra-
tio and more innovative ones such as B-lines or left ven-
tricular diastolic volume reserve) in the evaluation of
patients with known or suspected heart failure with pre-
served or mid-range ejection fraction. The secondary
aim is to assess the value of each of these parameters in
predicting the functional impairment, indicated by New
York Heart Association class, cardiac natriuretic pep-
tides concentration, peak VO2 and other indices. The
tertiary aim is to assess the prognostic value of SE indi-
ces for prognostic stratification of heart failure with pre-
served ejection fraction in the medium-long-term.
Methods
Patients with known or suspected heart failure with pre-
served ejection fraction by 2016 ESC criteria will be en-
rolled and studied with cycle-ergometer in semi-supine
SE (or treadmill). The test is especially indicated in pa-
tients with dyspnea and grade 1 diastolic dysfunction at
rest, identified as mitral E/A ratio ≤ 0.8, average E/e' ra-
tio < 10, peak tricuspid regurgitant jet velocity <2.8 m/s
and left atrium volume index normal (<34 mL/m2) or in-
creased [36]. In patients unable to exercise, pharmaco-
logical test of choice (dobutamine or vasodilator) is
allowed, but not recommended. The diastolic assessment
should be included into all exercise SE tests by measur-
ing standard Doppler-derived mitral inflow velocity,
pulsed Tissue Doppler of mitral annulus, and retrograde
tricuspid gradient of tricuspid regurgitation. These mea-
surements can be performed at intermediate load of ex-
ercise and/or 1- 2 min after the end of the exercise, after
obtaining wall motion acquisitions, when the heart rate
decreases and mitral inflow E and A velocities appear to
be well separated. As a part of the “diastolic package”,
we will also assess, at baseline, intermediate load (50
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watts) and peak-post stress [36]: diastolic left ventricular
volume index (to evaluate left ventricular diastolic
volume reserve, impaired in stiff hearts, which are less
dilated for any given filling pressure); systolic left ven-
tricular volume index (for assessment of left ventricular
elastance, which may unmask occult systolic dysfunction
with normal ejection fraction increase); ejection fraction
and both stroke volume and cardiac output (to assess
conventional contractile reserve); mitral regurgitation
and left ventricular outflow tract obstruction; pulmonary
artery systolic pressure (from velocity of tricuspid regur-
gitation); B-lines during stress (to provide a direct im-
aging of extra-vascular lung water accumulation as a
direct cause of dyspnea), since they can be present at
rest in diastolic heart failure [32]. Global longitudinal
strain could be optionally determined as the average of
the regional longitudinal strain measured in 17-
segments model from the apical long-axis, 4-chamber
and 2-chamber view. Despite not being independent on
preload and afterload, global longitudinal strain could be
considered as an appropriate, alternative parameter of
left ventricular contractile reserve [22, 39]. On the basis
of currently accepted criteria, the test is considered posi-
tive for diastolic dysfunction when all of the following
three conditions are met during exercise: average E/e' >
14 or septal E/e' ratio > 15, peak tricuspid regurgitant jet
velocity >2.8 m/s and septal e' velocity < 7 cm/s at base-
line [36].
Sample size calculation
The composite end-point of the study comprises death
(cardiovascular and all-cause), new hospital admission
for acute heart failure, aborted sudden death, heart
transplant or ventricular assist device implantation. The
expected incidence of events is around 20% per year
[10]. We assume a positivity rate to SE (by composite
criteria: increase in E/e' and/or increase in pulmonary
artery systolic pressure and/ or decrease in septal e' vel-
ocity and/or increase in B-lines) of 30%, with doubling
of likelihood of events in presence of SE positivity (by
any criteria). With a power of 80%, an alpha error of 5%,
and an attrition rate of 10% (for exams non-feasible and/
or for exclusion criteria during the screening phase due
to previously unrecognized dynamic severe mitral regur-
gitation or left ventricular outflow obstruction), a sample
size of about 250 patients is required.
Study hypothesis
In patients with known or suspected heart failure with
reduced ejection fraction, higher left ventricular filling
pressures, more B- lines and lower increases in end-
diastolic volumes during stress are associated with worse
prognosis.
SETA
Stress Echo in Transcatheter or surgical Aortic Valve
Implantation.
Background
Transcatheter Aortic Valve Implantation is an extraor-
dinarily effective but still a relatively novel technology,
and short and long term morbidity and mortality after
Transcatheter Aortic Valve Implantation remains signifi-
cant. There is substantial interest in the identification
and modification of factors influencing prognosis before
and after the procedure. The severity of concomitant mi-
tral regurgitation improves after the procedure in 2 out
of 3 patients, but baseline moderate-severe mitral regur-
gitation and significant residual mitral regurgitation are
associated with an increase in mortality after Transcath-
eter Aortic Valve Implantation and represent an import-
ant group to target with medical or transcatheter
therapies in the future [40]. Stress echo plays a pivotal
role in valvular heart disease [41], but its role after either
Transcatheter Aortic Valve Implantation or surgical re-
placement is still unsettled, although it has potential to
identify the presence and severity of mitral regurgitation
and aortic stenosis after intervention, so as to refine the
prognostic strategy and better tailor treatment.
Aims
The primary aim is to evaluate the feasibility of SE
focused on mitral and aortic reserve after aortic valve re-
placement (with Transcatheter or surgical aortic valve
implantation). The secondary aim is to assess the pres-
ence and entity of changes in valvular and ventricular
function and their correlation with indices of functional
severity (New York Heart Association Class, cardiac
natriuretic peptides, peak VO2, etc.).. The tertiary aim is
to assess the prognostic value of SE indices for prognos-
tic stratification in the medium-long-term.
Methods
Patients with previous (from 6 months to 10 years) sur-
gical or Transcatheter Aortic Valve Implantation capable
of exercising and with absent-to-moderate mitral insuffi-
ciency will be enrolled and studied with semisupine SE.
The full quantitative evaluation of mitral regurgitation
and aortic stenosis will be performed according to rec-
ommendations of the European Society of Cardiology. In
addition, assessment of B- lines (as in protocol 2), right
ventricular function (as in protocol 7), left ventricular
elastance (as in protocol 1) will be performed at baseline
and peak stress. Exercise will be started at 15 watts, with
5-min steps and 15-watt increments per step [13]. In
patients unable to exercise, a pharmacological test of
choice (dobutamine or vasodilator) is allowed, but not
recommended.
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Sample size calculation
The expected incidence of SE positivity (by composite
criteria: increase in mean transaortic gradient > 20 mmHg
and/or increase in mitral insufficiency > 1 grade and/or
increase in B-lines and/or increase in systolic pulmonary
artery pressure) is around 30% post- Transcatheter Aortic
Valve Implantation or aortic valve surgical replacement
[10]. With a power of 80%, an alpha error of 5%, and an
attrition rate of 10%, a sample size of about 100 patients is
required to detect a significant stress-induced increase in
mitral regurgitation severity. For the prognostic analysis
(tertiary end-point). If we conservatively assume a 20%
yearly incidence of composite end-points (death, myo-
cardial infarction, new hospital readmission, heart
transplant, ventricular assist device implantation,
aborted sudden death), with doubling of likelihood of
events in presence of a positive SE (for severe mitral in-
sufficiency and/or abnormally increased transaortic gra-
dient and/ or B-lines and/ or abnormal pulmonary
artery systolic pressure), with a power of 80% and an
alpha error of 5%, a sample size of about 250 patients is
required with a 3 -year follow-up.
Study hypothesis
In patients with absent-to moderate mitral regurgitation
in resting transthoracic echocardiography after either
surgical or Transcatheter Aortic Valve Implantation,
those with lower transaortic gradient and less mitral re-
gurgitation during stress will have a more favourable
outcome than patients with higher gradients and more
severe residual mitral regurgitation during stress.
SEO
Stress Echo Outdoor in Extreme conditions.
Background
SE with B-lines can also be performed outdoors, with
pocket size or portable instruments, in a setting of eco-
logical stress entirely different from standard indoor
testing [4]. The diagnostic target is the diagnosis, or
early subclinical identification, of life-threatening disease
at high altitudes or any kind of environmental pulmon-
ary edema. In this challenging but fascinating context,
lung ultrasound detects B-lines in 20 to 40% of normal
and/or super-fit subjects in extreme physiology settings,
such as high altitude [42, 43], deep underwater apnea
diving [44] or endurance exercise [45].
Aims
The primary aim is to evaluate the feasibility of outdoor
SE focused on B-lines in the logistic setting of extreme
physiology. The secondary aim is to assess the presence
and amount of B-lines increase at peak stress vs baseline
conditions (pre-exercise; pre-apnea; pre-ascent) and to
correlate lung ultrasound findings with symptoms (such
as dyspnea, cough, fatigue). The tertiary aim is to assess
the prognostic value of SE indices for predicting spon-
taneously occurring pulmonary edema.
Methods
Subjects involved in extreme sporting events (competi-
tive triathlon, marathon, apnea diving etc.) or ordinary
exercise in extreme environments (trekking at high alti-
tude) will undergo lung ultrasound scan for B-lines be-
fore, soon after (within 10 min) and (when positive soon
after) later after (6 to 24 h) the acute extreme exercise.
Additional clinical information will be collected in
addition to standard case report form (including Acute
Mountain Sickness scores in subjects evaluated at high
altitude), and will include details on type and duration of
exercise (apnea diving vs ascent trekking vs strenuous
exercise at sea level etc.) [43]; environmental conditions
(temperature, humidity, setting, wind etc.); location and
timing of scanning, with possibility of limited scanning
(8 regions instead of the standard 28) in more hostile
environments.
Sample size calculation
The expected incidence of SE positivity (increase in B-
lines >5 compared to rest) is around 30% [43]. With a
power of 80%, an alpha error of 5%, and an attrition rate
of 10%, a sample size of about 80 patients is required to
detect a significant stress-induced increase in B-lines in
each of the three major study subgroups: high altitude
trekkers (n = 100); marathon and ultra marathon runners
(n = 80) and apnea divers (n = 70).
Study hypothesis
Asymptomatic subjects with evidence of B- lines are
more likely to develop clinically overt forms of environ-
mental pulmonary edema with persistence of exposure
or in the future when re-challenged under similar
conditions.
SETOF
Stress Echo in operated Tetralogy of Fallot.
Background
Tetralogy of Fallot is the most common cyanotic con-
genital heart lesion, and since treatments became avail-
able over 70 years ago, there are now a large number of
patients with repaired Tetralogy of Fallot [46]. After
Tetralogy of Fallot repair, children often have residual le-
sions (the most common being pulmonary regurgitation)
which can be treated with surgical or catheter-based pul-
monary valve replacement decreasing right ventricular
size but not yet correlated with improved outcome [46].
Pulmonary regurgitation can cause progressive right
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ventricular dilatation and dysfunction. In Tetralogy of
Fallot patients morbidity and mortality are strongly re-
lated to right ventricular dysfunction. For this reason,
the early detection of right ventricular dysfunction be-
fore it reaches an irreversible stage remains crucial [47].
Unfortunately, resting parameters have shown a limited
ability to detect early impairment of right ventricular
function. Recently, a few studies have suggested that
physical or pharmacological stress may unmask abnor-
malities of right ventricular function in patients with
repaired Tetralogy of Fallot, with normal right ventricu-
lar function under resting conditions [48–50]. Physical
exercise SE allows the simultaneous assessment of right
and left ventricular global and regional function and
Doppler parameters [51].
Aims
The primary aim is to evaluate the feasibility of right
ventricular SE in patients with repaired tetralogy of
Fallot. The secondary aim is to assess the presence and
amount of right ventricular contractile reserve and its
correlation with indices of functional severity (NYHA
class, cardiac natriuretic peptides, peak VO2, 6-min
walking test, etc.). The tertiary aim is to assess the prog-
nostic value of SE indices for prognostic stratification in
the medium and long-term.
Methods
Patients with repaired Tetralogy of Fallot or Fallot-like
pathology (double-outlet right ventricle Fallot type, tet-
ralogy of Fallot with pulmonary atresia), evaluated at
least 1 year after the last surgical or percutaneous pro-
cedure, will be recruited by regional reference centers
for congenital heart disease. Additional inclusion criteria
are age > 10 years, height > 140 cm, New York Heart
Association class I or II. Right ventricular function will
be assessed at baseline and peak stress with variations
(rest and peak stress) of tricuspid annular plane systolic
excursion, an index of right ventricular longitudinal
function, and right ventricular fractional area change (a
load-dependent index of right ventricular inlet function).
Due to the influence of load on these measures, they
tend to reflect right ventricular arterial coupling rather
than measures of right ventricular contractility per se.
To distinguish between genuine right ventricular dysfunc-
tion and/or pathological increases in pulmonary vascular
load, whenever possible we will combine systolic pulmon-
ary artery pressure and right ventricular end-systolic area
using echocardiography to calculate right ventricular
end-systolic pressure-area relation as a surrogate of
right ventricular contractility [52].
Peak systolic tricuspid annulus velocity and conven-
tional indices of left ventricular systolic and diastolic
function will also be measured at baseline and peak
stress. Left ventricular function will also be assessed
through measurement of ejection fraction, wall motion
score index and E/e' at baseline and peak stress.
Sample size calculation
The expected incidence of SE positivity (by increase in
tricuspid annular plane systolic excursion < 5 mm) is
around 30% as shown by previous pilot studies [10].
With a power of 80%, an alpha error of 5%, and an attri-
tion rate of 10%, a sample size of about 250 patients is
required to detect a significant stress-induced increase
in tricuspid annular plane systolic excursion. For the ex-
ploratory prognostic analysis (tertiary end-point), we
conservatively assume a 20% yearly incidence of the pre-
determined end-point (death, myocardial infarction, new
hospital readmission, heart transplant, ventricular assist
device implantation, aborted sudden death), with doub-
ling of likelihood of events in presence of a positive SE
(reduced right ventricular contractile reserve). With a
power of 80% and an alpha error of 5%, a sample size of
about 250 patients is required with a 3 -year follow-up.
Study hypothesis
Repaired tetralogy of Fallot patients with better right
(and possibly left) ventricular reserve will have less
chance of developing adverse events in their natural
history.
DOSPAH
Doppler Stress echo in Pulmonary Arterial Hypertension.
Background
Patients at risk of pulmonary arterial hypertension at rest
may show abnormal flow-adjusted increase in pulmonary
pressures during exercise and are more likely to develop
subsequent resting pulmonary hypertension [53, 54]. In pa-
tients with established or borderline pulmonary arterial
hypertension capable of exercising, the level of exercise-
induced increase in systolic pulmonary artery pressure and
a reduced right ventricular contractile reserve are associ-
ated with a poorer prognosis [55]. The potential value of
exercise-stress echo can be diagnostic in patients at risk of
pulmonary arterial hypertension, and prognostic in patients
with early established or borderline pulmonary arterial
hypertension (Group 1 of European Society of Cardiology
guidelines 2015) [56].
Aims
The primary aim is to evaluate the feasibility of SE
focused on pulmonary hemodynamics and right ven-
tricular function in patients at risk, borderline or early
established pulmonary arterial hypertension. The sec-
ondary aim is to assess the presence and amount of right
ventricular contractile reserve and its correlation with
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indices of functional severity (New York Heart Associ-
ation Class, cardiac natriuretic peptides, peak VO2, etc.).
The tertiary aim is to assess the prognostic value of SE for
predicting increase of resting systolic pulmonary artery
pressure in the medium-term (2-years follow-up).
Methods
Patients at risk, borderline, or early established pulmon-
ary hypertension capable of exercising will be recruited
by regional reference centers for pulmonary hyperten-
sion. A physical stress with exercise will be performed. A
thorough non-invasive hemodynamic assessment will be
performed, including evaluation of rest and peak stress
of: 1) Systolic pulmonary artery pressure from maximal
velocity of tricuspid Doppler regurgitant jet adding the
value of the right atrial pressure estimated on the basis
of diameter and inspiratory collapse index of the inferior
vena cava [57]; 2) mean pulmonary artery pressure as
0.6 x systolic pulmonary artery pressure +2 [58]; 3) car-
diac output from the time-velocity integral of the left
ventricular outflow tract [59]. SE positivity criteria will
be the absolute increase in systolic pulmonary artery
pressure >50 mmHg or the delta mean pulmonary arter-
ial pressure/cardiac output > 3 mmHg/L/min. When a
good-quality tricuspid jet signal cannot be sampled, the
mean pulmonary artery pressure will be estimated based
on pulsed-Doppler measurement of the acceleration
time of pulmonary flow, sampled at the right ventricular
outflow tract as mean pulmonary arterial pressure =79 -
(0.6 x Acceleration time) [60]. Right ventricular contractile
reserve will be measured as described above in project 7.
Sample size calculation
The expected incidence of SE positivity is around 30% as
shown by previous pilot studies [10]. With a power of
80%, an alpha error of 5%, and an attrition rate of 10%, a
sample size of about 250 patients is required to detect a
significant stress-induced hemodynamic changes. For
the prognostic analysis (tertiary end-point), if we conser-
vatively assume a 15% yearly incidence of the pre-
determined end-point (increase in resting systolic
pulmonary artery pressure > 35 mmHg), with doubling of
likelihood of events in presence of a positive SE, with a
power of 80% and an alpha error of 5%, a sample size of
about 250 patients is required with a 3 -year follow-up.
Study hypothesis
In subjects at risk of pulmonary arterial hypertension,
those with higher pulmonary artery systolic pressure and
lower decrease in pulmonary vascular resistance (as
delta mean pulmonary arterial pressure/cardiac output
>3 mmHg/L/min) during exercise will have more chance
of developing resting pulmonary hypertension in their
natural history [59, 60]. In patients with established early
or borderline pulmonary arterial hypertension, those
with lower decrease in pulmonary vascular resistances
and worse right ventricular contractile reserve during
exercise will have more chances of developing adverse
events in their natural history.
DITSE
Diagnosis of CAD by Triple imaging Stress Echo (wall
motion, coronary flow reserve and left ventricular elas-
tance) plus B-lines.
Background
The cornerstone of diagnosis with SE is the finding of
reversible regional wall motion abnormalities. However,
the potentially valuable, diagnostic and prognostic, infor-
mation provided by SE extends well beyond regional
wall motion. In vasodilator and also during exercise
stress, a clear step-up in diagnostic sensitivity (with a
modest loss in specificity) and risk stratification capabil-
ity is obtained with assessment of coronary flow velocity
reserve in the left anterior descending coronary artery
[61–63]. In exercise and dobutamine, and also with
vasodilator stress, critical gains in sensitivity can be
achieved by non invasive assessment of left ventricular
contractile reserve through changes in left ventricular
elastance, a load-independent index of left ventricular
contractility more diagnostically and prognostically valuable
than changes in ejection fraction [64, 65]. Normal values of
coronary flow velocity reserve are >2.0 for all stresses, while
the contractile reserve normal values are >2.0 for exercise
and dobutamine but >1.0 for vasodilator stress. Further-
more, evaluation of B-lines can introduce a variable of add-
itional prognostic value indicating acute accumulation of
extra-vascular lung water [30, 31].
Aims
The primary aim is to evaluate the feasibility (with dif-
ferent stresses and protocol, with or without contrast) of
rest and stress-induced integrated approach during SE
with the “quadruple imaging” approach: regional wall
motion abnormalities (standard, single imaging ap-
proach), coronary flow velocity reserve on left anterior
descending (advanced, dual imaging approach); left ven-
tricular elastance (derived from simple raw measures of
cuff sphygmomanometer systolic arterial pressures/end-
systolic volume, triple imaging approach); extra-vascular
lung water (derived from B-lines from lung sonography,
quadruple imaging approach). The secondary aim is to
assess the diagnostic value of each of these parameters
(alone and in combination) in predicting underlying cor-
onary anatomy independently assessed by cardiac com-
puted tomography and/or invasive coronary angiography
(required when cardiac computed tomography is posi-
tive). The tertiary aim is to assess the prognostic value
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of the integrated SE in predicting events in the medium-
term follow-up (up to 2 years)
Methods
All patients (“allcomers”) referred to the SE lab with sus-
pected CAD (history of chest pain or asymptomatic with
previous positivity of any stress test, different from SE)
will be evaluated with standard regional wall motion
analysis and also – whenever feasible - with left ven-
tricular coronary flow reserve (at least on the left anter-
ior descending coronary artery) and left ventricular
elastance reserve (whatever the stress: exercise, vasodila-
tor or dobutamine). B-lines can be assessed at baseline
and soon after stress. For each stress, all the four indices
(regional wall motion, coronary flow velocity reserve, left
ventricular elastance reserve and B-lines) can be obtained,
if possible. For coronary flow velocity reserve assessment
on left anterior descending, both the maximum diastolic
flow velocity and, when possible, the whole envelope to ex-
trapolate the new parameter labelled coronary functional
reserve will be measured. Also patients with known CAD
referred to SE for prognostic stratification will be included
and evaluated for prognostic outcome, including (when
feasible) resting transthoracic echocardiography evaluation
of regional and global left ventricular function to assess
progression to left ventricular dilation and dysfunction
(ejection fraction decrease of > 15% and below 35%).
Centers can recruit with any combination of dual im-
aging (regional wall motion plus at least one of the three
more innovative parameters: coronary flow velocity re-
serve, left ventricular contractile reserve and B-lines) as
dictated by the locally available technology and expertise.
According to preliminary experience, the feasibility rate
is expected to be highest for left ventricular contractile
reserve and B-lines, and lower for more demanding cor-
onary flow velocity reserve.
Sample size calculation
The expected incidence of SE positivity (by composite
criteria: regional wall motion abnormalities in 10%; reduc-
tion in coronary flow reserve velocity in 30%, blunted left
ventricular contractile reserve in 20%; B-line increase >5)
is around 35% [10]. A subset of 500 patients with coronary
angiography verification (by invasive angiography or cor-
onary CT) is required for reliable estimates of feasibility,
imaging time and analysis time of each parameter. For
prognostic tertiary end-point, if we conservatively assume
a 5% yearly incidence of composite end-points (death,
myocardial infarction, new hospital readmission, heart
transplant, ventricular assist device implantation, aborted
sudden death), with doubling of likelihood of events in
presence of a positive SE (for composite criteria), with a
power of 90% and an alpha error of 5%, a sample size of
about 2500 patients is required with a 3-year follow-up. If
only mortality is considered, a sample size of about 5,000
patients will be required.
Study hypothesis
Quadruple imaging combining coronary flow velocity re-
serve on left anterior descending artery, left ventricular
contractility reserve evaluation with elastance assess-
ment and B-lines in addition to conventional regional
wall motion analysis is feasible with reasonable success
rate, and diagnostically useful in all patients with all
stresses. Even in the absence of inducible regional wall
motion abnormalities, a lower coronary flow velocity re-
serve on left anterior descending coronary artery and/or
a reduced left ventricular contractile reserve and/or an
increase in B-lines will identify patients with worse out-
come. When feasible, the combination of the quadruple
imaging (regional wall motion, coronary flow reserve,
left ventricular elastance reserve and B-lines) yields more





The identification of phenotype-negative and genotype
positive carriers of pathologic mutations is an important,
yet still elusive, target for clinical cardiologists, although
encouraging preliminary results have been reported with
SE allowing identification of dynamic gradients in hyper-
trophic cardiomyopathy mutation carriers prior to devel-
opment of hypertrophy [66], increased pulmonary
resistance in mutation carriers of familial pulmonary
hypertension with normal pulmonary pressure at rest
[67], and higher resting end-diastolic volumes and pos-
sibly reduced contractile reserve during stress in familial
dilated cardiomyopathy mutation carriers with normal
left ventricular function at rest [68].
Aims
The primary aim is to evaluate the feasibility of SE in
genetically characterized (on the basis of existing recom-
mendations) first-degree relatives of patients with genetic-
ally transmitted cardiac diseases (such as hypertrophic
cardiomyopathy, familial pulmonary arterial hypertension,
and familial dilated cardiomyopathy). The secondary
aim is to assess the value of disease-specific sentinel-
parameters during SE in predicting the carrier and
non-carrier status of healthy asymptomatic relatives,
with the carrier status predicted by increased left ventricu-
lar outflow tract gradient in hypertrophic cardiomyopathy,
exaggerated rise in systolic pulmonary arterial pressure in
familial pulmonary arterial hypertension, and by blunted
left ventricular contractile reserve in familial dilated
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cardiomyopathy. The tertiary, exploratory aim is to assess
the value of SE indices for predicting the phenotypic ex-
pression of the disease in the medium-long term.
Methods
We will initially select 75 patients (25 for each disease)
with documented disease and mutant gene identified by
next-generation sequencing platform using targeted dis-
ease gene panels in tertiary care centers of genetic cardi-
ology (in Florence-Careggi, Naples-Monaldi, Pisa-CNR
or Cattinara-Trieste); they will undergo standardized SE
testing. Furthermore, we will enroll around 250 first-
degree relatives of the initially considered probands, with
similar number for each disease, all with good-quality
echocardiographic imaging, normal findings at rest and
age range preferentially between 10 and 21 years (since a
pathological phenotype is more likely to develop in the
following 5 years when a diseased genotype is present).
The relatives will undergo both genetic testing for the
gene identified in the proband and SE testing with cen-
tralized core lab reading by observers blinded to genetic
testing results. Each SE testing will be tailored on the
specific question: hypertrophic cardiomyopathy as in
protocol 3 (primary endpoint: orthostatic exercise in-
duced change in left ventricular outflow tract gradient);
pulmonary hypertension as in protocol 8 (primary end-
point: rest-exercise, flow-adjusted, variation in pulmon-
ary vascular resistances); dilated cardiomyopathy as in
protocol 1 (primary endpoint: left ventricular elastance
change following exercise). All enrolled subjects (both
genotype-positive and genotype-negative) will undergo
yearly clinical and resting transthoracic echocardiog-
raphy follow-up. The criteria for disease detection in
these individuals include minimal phenotypes with low
cut-off values (a wall thickness > 13 mm in the anterior
septum and/or posterior left ventricular wall for hyper-
trophic cardiomyopathy; resting pulmonary artery systolic
pressure > 40 mmHg verified by cath lab for primary pul-
monary hypertension; a dilated left ventricular end-diastolic
volume index > 74 mL/m2 for men or 61 mL/m2 for
women and/or ejection fraction < 45% for dilated cardiomy-
opathy) [22]. In all subjects, coronary flow reserve during
exercise will be evaluated, since a coronary microvascular
abnormality has been reported as a very early finding in
both dilated and hypertrophic cardiomyopathy, and this
technique, albeit demanding, is feasible with last generation
technology also during exercise [63].
Sample size calculation
We conservatively assume a significant increase in left
ventricular outflow tract gradient > 50 mmHg during ex-
ercise in 50% of mutation carriers (as shown in a pilot
study, 66) versus 5% of non-carriers. A significant differ-
ence in prevalence of left ventricular outflow tract
gradient will be observed, with a power of 80% and an
alpha error of 5% with an attrition rate of 10%, with a
sample size of about 80 patients for the hypertrophic
cardiomyopathy study. A similar sample size estimation
is applied to the other two subprojects of familial dilated
cardiomyopathy (primary SE endpoint: increase in left
ventricular contractile reserve <2.0) and familial pul-
monary hypertension (primary SE endpoint: increase in
systolic pulmonary artery pressure > 50 mmHg), with a
total sample size of about 250 subjects for the whole
subproject.
Study hypothesis
SE abnormalities predict carrier status in families with
genetic cardiomyopathies. In genetic carriers, SE abnor-
malities may predict development of overt disease at
mid-term follow-up.
Discussion
The overarching aim of SE2020 is to provide data directly
relevant to patient care by filling the existing evidence gap
in several areas of SE. Due to health care rationing and
shortage of resources for independent, patient-oriented re-
search, the SE community should face the challenge to
optimize the use of infrastructural resources to provide
the evidence base necessary for tailoring the right SE to
the right patient with the right technology, used by the
right (properly trained and certified) cardiologist.
There are several possible kinds of added values in this
project.
Clinical
Only multicenter trials can provide the necessary infor-
mation for validation of any diagnostic procedure in a
reasonable amount of time; otherwise, tests that are haz-
ardous or unfeasible, or both, may become accepted be-
fore inadequacies are recognized. SE is widely validated
and has stood the test of time, but this is true mainly (if
not only) for CAD and heart failure applications based
on regional wall motion abnormalities. New applications
are conceptually innovative, based on various parame-
ters, applied to different patients, and we cannot skip
the chain of validation required to transform a promis-
ing innovation into an established procedure [3, 4].
Scientific
Enrollment of patients in 10 different studies of special
interest will provide a considerable amount of unique in-
formation in a relatively short time in several areas of
critical scientific interest. In particular, in all of these
fields available prognostic data are absent or, when exist-
ent, suffer from relatively small sample size and include
soft and heterogeneous end-points to document prog-
nostic power. The study will also generate an intellectual
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and professional network which is the ideal platform for
future randomized, outcome intervention trials to assess
the value of SE-based interventions, which is the highest
level of evidence required by guidelines to change
current clinical practice and yet lacking to date for sev-
eral new applications of cardiac imaging [3, 4].
Educational
With a coordinated effort endorsed by the Italian Society
of Cardiovascular Echography, the stress echo community
will develop, test in the field and disseminate a structured
software for collecting medical history, demographic infor-
mation, clinical, SE, other imaging techniques, and out-
come data for patients entering the standardized Italian
and international “SE lab without walls”. The participants
to this SE lab will voluntarily agree to share a common
language of indications, execution, reporting, image stor-
age and archiving SE information performed in accredited
centers, which previously underwent quality control of
reading for specific SE skills. This will help to advance the
field of SE, minimizing the greatest weakness of the tech-
nique, i.e., inter-laboratory variability in reading criteria,
reporting heterogeneity and lack of permanent quality
control standards [16, 17].
Economic
Today SE enjoys the advantages of economic sustainabil-
ity and lack of radiation, making it potentially dominant
in the current era of health care rationing [69]. However,
to be cost-effective the indication must be appropriate,
the exam must be performed by trained personnel, and
with robust evidence supporting its specific clinical use.
Otherwise, SE becomes just another tree in the cardiac im-
aging forest of inappropriate and redundant testing [70].
Comparison with previous studies
The same conceptual and operative template of SE2020
was put in place almost 30 years ago, at the beginning of
the SE era, when the Italian first-generation multicenter
studies provided unique evidences for the use of pharma-
cological testing with dipyridamole (EPIC; Echo-Persantine
International Cooperative) study and dobutamine (EDIC,
Echo-Dobutamine International Cooperative) study for the
diagnosis of coronary artery disease. They addressed key as-
pects of stress testing such as safety and prognostic value in
specific patient subsets [71–74]. From 1992 to 2012, over
30 articles from this multicenter trial network were pub-
lished in top peer-reviewed journals and more importantly,
these results rapidly shaped clinical practice and scientific
guidelines [5, 6], since practice is easier to change when
based on evidence that someone contributed to building in
his/her own laboratory. In the footsteps of this template,
the same paradigm will be followed today with SE2020
(Table 2). At that time, the main focus was on CAD; today,
on conditions beyond CAD. Yesterday, the key sign was
wall motion with 2-D, today an array of disease-specific
diagnostic markers (from B-lines with lung ultrasound to
coronary flow reserve with pulsed Doppler). At that time,
early adopters were interested mainly for scientific reasons;
today, virtually every lab can play a role, and is motivated
by clinical interest to share experiences and standardize
languages in a widely deregulated field. Yesterday, the driv-
ing force and core team of investigators came from a re-
search institute (Italian National Research Council) with a
top-down approach, from a research vision; today, from a
scientific society (Italian Society of Echocardiography) net-
working all interested clinical cardiologists with an inclusive
approach generating a bottom-up strategy, where all differ-
ent expertise is added in a common intellectual architec-
ture. The rationale of first- and second-generation studies
is the same. As scientists and as clinicians, we need to act
on the basis of effectiveness, real-world data populated by
real patients, real doctors and real problems rather than on
published efficacy data collected in ideal conditions but not
always representative of true life. The seed of efficacy
should not be mistaken for the fruit of effectiveness, which
is the value of the technique when deployed in the field.
We need the fruit of effectiveness, not the seed of efficacy,
to feed our patients. We also learned from the decades of
experience with first-generation multicenter trials that sim-
ple protocols without economic induction can change
guidelines, and cardiologists interested in SE are generous
with their time and willing to do things that help them to
work better and offer a contribution to clinically meaning-
ful, patient-oriented research [19].
One generation later, in a totally different economic
and scientific healthcare scenario, once again Italian and
international cardiology creates a network to build up
the missing evidence. At least in principle, SE2020 fully
shares the four cornerstones of the landmark mega-trial
GISSI, Gruppo Italiano Studio Streptochinasi nell’ Infarto,
which can be summarized as follows [75]: 1) sponsorship
by a respected, independent, not-for profit national society:
it was the national Association of Hospital Cardiologists for
Table 2 Stress echo multicenter trials
Years 1990-2010 2016-2030
Study acronym EPIC and EDIC SE 2020
Main focus CAD CAD and beyond
Enrolling centers criteria Selective Inclusive
Stress Dip and Dob Exercise, dip (ado) and dob
Key parameters RWMA CFVR, B-lines, E/e’, etc.
Participating centers 10+ 100+
Scientific societies role Absent Proactive
CAD coronary artery disease, CFVR coronary flow velocity reserve, EDIC echo-
dobutamine international cooperative study, EPIC, echo-persantine international
cooperative study, RWMA regional wall motion abnormalities
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GISSI, and now it is the Italian Society of Echocardiography
for SE2020; 2) scientific coordination by a professional,
public research institute: it was the Mario Negri of Milan
for GISSI, it is now the National Research Council of Pisa
for SE2020; 3) inclusivity, with the involvement of nearly all
the interested professionals in the nation: it was over 300
coronary care units in GISSI, it is now > 100 echocardi-
ography labs in SE2020; and 4) emphasis on clinically rele-
vant topic and outcomes that directly impact every day
patient care: it was thrombolytic therapy for GISSI, it is
now be cardiac imaging in and outside CAD for SE2020.
Hopefully, the results will help improve the practice stan-
dards for the Italian cardiology and echocardiographic
community across the nation and the available practice-
changing scientific evidence worldwide. In a rapidly evolv-
ing SE field, SE 2020 addresses the need for standardization
clearly identified by the American Society of Echocardiog-
raphy roadmap to 2020 in its research and technology rec-
ommendations [76]. The development of research registries
is identified as a potentially important tool for assessing
and improving the quality of care and a valuable platform
for clinical research. Such registry data would be accessible
to the research community, facilitating a broad range of
clinical research on the effectiveness of echocardiography
(in this case, of SE) for the improvement of patient manage-
ment and outcome [76].
Conclusion
The study officially starts in the very same days when
American poet and singer Bob Dylan is awarded the No-
bel prize for literature in December 2016 – and perhaps
also for SE "the times they're in a-changin' ". SE2020 will
coordinate and channel the efforts of the echocardio-
graphic community to keep SE where it stands now – at
center stage in guidelines of CAD and heart failure –
and to move on beyond CAD and above regional wall
motion abnormalities, filling in the gaps in a currently
evidence-poor field: "The line it is drawn, the curse it is cast.
The slow one now will later be fast, as the present now will
later be past, the order is rapidly fadin'. And the first one
now will later be last, for the times they are a changin'".
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